News & Updates

Vupanorsen reduces non-HDL-C levels in adults with hyperlipidaemia already on statins

15 Apr 2022 by

Vupanorsen significantly reduces non–high-density lipoprotein cholesterol (non-HDL-C) levels in adults with hyperlipidaemia already taking statins, according to the TRANSLATE-TIMI 70* trial presented at ACC 2022.

Vupanorsen reduces non-HDL-C levels in adults with hyperlipidaemia already on statins

15 Apr 2022

Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer

14 Apr 2022 by

Maintenance treatment with selinexor improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer who had previously received first-line chemotherapy, particularly those with endometrioid histology and wild-type p53, according to a study presented at SGO 2022.

Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer

14 Apr 2022

Tamsulosin–mirabegron combo improves urination frequency but not voiding volume

14 Apr 2022

Treatment with the combination of tamsulosin plus mirabegron following 125I-brachytherapy for prostate cancer falls short of improving voiding volume compared with tamsulosin monotherapy, although the combination helps with urination frequency and overactive bladder symptoms, according to a study.

Tamsulosin–mirabegron combo improves urination frequency but not voiding volume

14 Apr 2022

Nivolumab-based regimen confers OS benefit, durable responses in advanced ESCC

14 Apr 2022 by

First-line treatment with nivolumab – be it in combination with chemotherapy (CT) or with ipilimumab – provided overall survival (OS) benefit and durable responses than CT alone in patients with advanced oesophageal squamous cell carcinoma (ESCC), according to findings from the phase III CheckMate 648 trial.

Nivolumab-based regimen confers OS benefit, durable responses in advanced ESCC

14 Apr 2022

Mix-and-match better than same-type booster vax against COVID-19

13 Apr 2022 by

Getting a heterologous vaccine booster appears to confer a greater protection against COVID-19 than homologous booster, suggest data from a Singapore study.

Mix-and-match better than same-type booster vax against COVID-19

13 Apr 2022

Chronic opioid use occurs in head and neck cancer patients on radiation therapy

13 Apr 2022

Patients with head and neck cancer who undergo radiation therapy tend to have persistent opioid use, reveals a study, noting further investigation on early intervention to appropriately wean patients.

Chronic opioid use occurs in head and neck cancer patients on radiation therapy

13 Apr 2022

Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab

12 Apr 2022 by

Ustekinumab is well tolerated and proves to be effective in the second-line treatment of patients with Crohn’s disease, according to real-world data from the Cross Pennine II study. Furthermore, while clinical remission appears to occur sooner with ustekinumab than with vedolizumab, the two drugs perform comparably at maintaining remission over 12 months.

Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab

12 Apr 2022

Statins provide consistent protection against biliary tract cancers

12 Apr 2022

For chemoprevention for biliary tract cancers (BTC) and its subtypes, statins appear to confer benefits whereas low-dose aspirin does not, according to a study. Moreover, the addition of low-dose aspirin to statins contributes no further reduction in the risk.

Statins provide consistent protection against biliary tract cancers

12 Apr 2022

Adding alirocumab to rosuvastatin reduces coronary plaque in patients with acute MI

12 Apr 2022 by

Adding alirocumab to rosuvastatin led to a significantly reduced coronary plaque in noninfarct-related arteries in patients with acute myocardial infarction (MI), according to the PACMAN-AMI* trial presented at ACC 2022.

Adding alirocumab to rosuvastatin reduces coronary plaque in patients with acute MI

12 Apr 2022

First-line niraparib maintenance regimen boosts PFS in advanced ovarian cancer

11 Apr 2022 by

First-line maintenance therapy with niraparib at an individualized starting dose (ISD) improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, according to results of the phase III PRIME study presented at SGO 2022.

First-line niraparib maintenance regimen boosts PFS in advanced ovarian cancer

11 Apr 2022

News & Updates

Filter by Specialty:

Specialty:

Vupanorsen reduces non-HDL-C levels in adults with hyperlipidaemia already on statins

Vupanorsen reduces non-HDL-C levels in adults with hyperlipidaemia already on statins

Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer

Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer

Tamsulosin–mirabegron combo improves urination frequency but not voiding volume

Tamsulosin–mirabegron combo improves urination frequency but not voiding volume

Nivolumab-based regimen confers OS benefit, durable responses in advanced ESCC

Nivolumab-based regimen confers OS benefit, durable responses in advanced ESCC

Mix-and-match better than same-type booster vax against COVID-19

Mix-and-match better than same-type booster vax against COVID-19

Chronic opioid use occurs in head and neck cancer patients on radiation therapy

Chronic opioid use occurs in head and neck cancer patients on radiation therapy

Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab

Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab

Statins provide consistent protection against biliary tract cancers

Statins provide consistent protection against biliary tract cancers

Adding alirocumab to rosuvastatin reduces coronary plaque in patients with acute MI

Adding alirocumab to rosuvastatin reduces coronary plaque in patients with acute MI

First-line niraparib maintenance regimen boosts PFS in advanced ovarian cancer

First-line niraparib maintenance regimen boosts PFS in advanced ovarian cancer